ReviewCurrent pain and headache reports2026
Pivotal Factors for Minimizing the Risks of Therapeutic Failure in Trigeminal Neuralgia and Hemifacial Spasm.
Review in Current pain and headache reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDespite the scarce literature regarding the matter, this current article identifies the most important factors that lead to the best outcomes in the therapeutic approach of trigeminal neuralgia and hemifacial spasm. However, notwithstanding the central focus lies on the neurosurgical perspective, the authors also integrate insights from adjacent medical specialties. Thus, the main objective of this comprehensive narrative review is to enhance understanding of the factors that can dramatically influence the course of these conditions. RECENT
findingsThis article provides a state-of-the-art perspective regarding the therapeutic management of trigeminal neuralgia and hemifacial spasm. Preoperative diagnosis has the first pivotal role in managing this condition, and 3D multimodal image fusion based on Time-Of-Flight Magnetic Resonance Angiography (TOF MRA) with high-resolution T2-weighted imaging has been proven to be the most effective and accurate method. Focusing on the correct therapeutic approach is the second pivotal factor, given that the therapeutic options comprise various approaches ranging from oral medication to neurosurgical microvascular decompression. It has been concluded that microvascular decompression remains the most effective treatment for drug-resistant trigeminal neuralgia and hemifacial spasm. Pain freedom is achieved in around 76-84% of patients, and long-term durability remains substantial, with 64-73% still pain-free at ten years, particularly when the compression is arterial rather than venous. The endoscopic approaches demonstrated efficacy in selected cases, while combined procedures such as MVD with partial sensory rhizotomy may increase numbness without improving long-term results. Systematic reviews concluded that radiosurgery and percutaneous procedures can provide pain relief in many patients, but with less durable outcomes. Altogether, these findings support MVD as the cornerstone surgical therapy while underlining the importance of careful patient selection and modern adjuncts to maximize success. When the neurosurgical intervention represents the treatment option for trigeminal neuralgia or hemifacial spasm, several pivotal factors must be taken into account in order to provide the best clinical results with minimal to no complications.
Indexed as
Identifiers
41642504What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.